Imaging Biomarkers in Preclinical and Symptomatic AD
Status:
Recruiting
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate adult children of parents with and without
Alzheimer's disease which represent an ideal population for investigating the biological
changes that precede the clinical onset of AD. The investigators will be imaging the brain to
detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may
be related to dementia of Alzheimer's disease (DAT).
This study will use a radioactive tracer called [11C]-Pittsburgh Compound B (11C]PIB), which
is a tracer that binds to beta amyloid protein in the brain. This compound is considered
investigational, which means that it has not been approved by the United States Food and Drug
Administration (FDA).